CEO’s statement
“It is with great pleasure that I present another strong quarterly report. We have achieved positive net earnings, excluding goodwill amortization, and are now well on our way to sustainable profitability. Sales increased significantly, confirming that our strategic focus on growing within existing markets is working. At the same time, we prioritize profitability and are adapting our organization and production capacity in an economically responsible manner to ensure stable and long-term growth.

During the quarter net earnings, excluding goodwill amortization, came in at just over 50 KSEK, and we achieved a positive EBITDA of just over 160 KSEK. This is in line with our plan to build a successful diagnostics company.

Revenue increased by an impressive 31% during the quarter compared to the same quarter last year, and by 25% for the first nine months of the year compared to the previous year. We can now state that we have four years of steady sales growth behind us. The pace of sales growth has accelerated over the past year, and we see continued strong order intake, which bodes well for the future”.

Anders Hultman, CEO

Reporting period July 1st – September 30th

• Net sales amounted to KSEK 13,996 (10,700).
• Profit after financial items amounted to KSEK -9,841 (-13,003) *.
• Cash flow from operating activities for the period amounted to KSEK -4,161 (-5,661).
• Earnings per share before and after dilution amounted to SEK -0.04 (-0.06).
• Cash and cash equivalents at the end of the period amounted to KSEK 44,535 (51,512).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Reporting period January 1st – September 30th

• Net sales amounted to KSEK 42,072 (33,528).
• Profit after financial items amounted to KSEK -33,437 (-42,161) *.
• Cash flow from operating activities for the period amounted to KSEK -5,608 (-12,525).
• Earnings per share before and after dilution amounted to SEK -0.15 (-0.18).
• Cash and cash equivalents at the end of the period amounted to KSEK 44,535 (51,512).

* Includes costs for goodwill amortization of KSEK 29,684 (29,684) for the quarter.

Interim report January 1st – September 30st, 2024 (Link)

CEO’s statement
“I am very pleased to announce that our growth focus within existing markets is yielding results. We are experiencing a significant increase in sales while simultaneously adjusting our organization and production capacity in an economically sustainable manner to ensure continued stable growth. In parallel, we also aim to broaden our product portfolio through in-licensing or acquisition. During the second quarter, we achieved a positive cash flow of SEK 2.4 million, which marks an important step forward in our efforts to build a successful diagnostics company.

Revenue increased by 30% compared to the same quarter last year and by nearly 20% compared to the first quarter. We are now in our fourth consecutive year of strong sales growth. Compared to the first half of 2023, sales have grown by 23%, and we continue to see very strong order intake”.

Anders Hultman, CEO

Reporting period April 1st – June 30th

• Net sales amounted to KSEK 15,273 (11,775).
• Profit after financial items amounted to KSEK -13,054 (-15,490) *.
• Cash flow from operating activities for the period amounted to KSEK 2,767 (-2,342).
• Earnings per share before and after dilution amounted to SEK -0.06 (-0.07).
• Cash and cash equivalents at the end of the period amounted to KSEK 48,705 (57,548).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Reporting period January 1st – June 30th

• Net sales amounted to KSEK 28,076 (22,828).
• Profit after financial items amounted to KSEK -23,594 (-29,158) *.
• Cash flow from operating activities for the period amounted to KSEK -1,447 (-6,864).
• Earnings per share before and after dilution amounted to SEK -0.10 (-0.13).
• Cash and cash equivalents at the end of the period amounted to KSEK 48,705 (57,548).

* Includes costs for goodwill amortization of KSEK 19,789 (19,789) for the quarter.

Events during the period April 1st – June 30th

• April 5-8 - AroCell’s marketing and clinical team alongside with our partners Prof Thorsten Ecke and Dr. Sarah Weiss from Germany participated in the 39th annual European Association of Urology Congress. Where our team presented a poster titled “Effect of hematuria on the performance of BTAstat®, UBC® Rapid, and NMP22 as urine-based biomarker for bladder cancer detection“.

• April 5-10 - AroCell visited American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, where our team delivered two impactful poster presentations. Professor Teemu Murtola highlighted the TK 210 ELISAs predictive role of castration resistance in metastatic prostate cancer, while Kiran Jagarlamudi, CSO from AroCell, presented the clinical applications of TK 210 ELISA in DLBCL therapy.

• April 12 - AroCell published the Annual Report for 2023.

• April 18 - A new patent has been approved in the USA. The patent protects AroCell's specific antibodies that bind to the C-terminal region of TK1. These antibodies are used to measure TK1 protein in serum for cancer diagnostics.

• April 22 - AroCell published the notice for the Annual General Meeting for 2024.

• May 22 - AroCell published the report from the Annual General Meeting for 2024.

• June 19 - A delegation from Airlangga University and Dr. Soetomo General Hospital visited the AroCells office in Stockholm. Airlangga University, one of the oldest medical schools in Indonesia, and Dr. Soetomo General Hospital, the largest teaching hospital in Eastern Indonesia, both have centers for Tropical Disease and Cancer research.

Interim report January 1st – March 31st, 2024 (Link)

CEO’s statement

“The year 2024 started successfully with solid sales in the first quarter and continued strong order intake for the coming quarter. Production is operating at high speed ensuring that deliveries progress well. Financial results look promising and we are following our strategic plan towards profitability. Excluding goodwill amortization, the period’s result was -600 KSEK and we achieved a positive EBITDA of nearly 600 KSEK, which feels reassuring.”

Anders Hultman, CEO

Reporting period January 1st – March 31st

• Net sales amounted to KSEK 12,803 (11,053).
• Profit after financial items amounted to KSEK -10,505 (-13,668)*.
• Cash flow from operating activities for the period amounted to KSEK -4,214 (-4,522).
• Earnings per share before and after dilution amounted to SEK -0.05 (-0.06).
• Cash and cash equivalents at the end of the period amounted to KSEK 46,347 (59,956).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Events during the period January 1st – March 31st

• A recently conducted study has shown that levels of serum thymidine kinase 1 (sTK1) can predict the survival of patients with metastatic prostate cancer. The study also indicates that sTK1 is useful for predicting which patients may benefit from chemotherapy with the drug docetaxel, instead of hormonal treatment.

• AroCell has previously announced that it has entered into a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sale of TUBEX® TF in Ethiopia. After working through the local regulatory process, AroCell has now obtained regulatory approval for TUBEX® TF in Ethiopia.

• Ellen Dittberner, CFO of AroCell, has taken maternity leave, and Lars Jakobsson has assumed the role of acting CFO.

• Two abstracts regarding the clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at AACR 2024.

• A new study examining the use of urine-based biomarkers, including UBC Rapid, for monitoring patients with high-risk non-muscle-invasive bladder cancer has been published.

• The Nomination Committee has presented proposals for the board of directors at AroCell for the Annual General Meeting 2024, where Max Pihlqvist is proposed as the chairman of the board and Fredrik Lindgren is proposed for election as a new board member.

Events after the period

• AroCell published the Annual Report for 2023.

• A new patent was approved in the USA. The patent demonstrated the clinical significance of TK1 protein measurements in serum with specific antibodies against the C-terminal region of TK1 in cancer.

• AroCell published the notice for the Annual General Meeting in 2024.

Interim report January 1st – March 31st, 2024 (Link)

A word from the CEO
”2023 has proven to be a successful year for AroCell. We have observed consistent strong demand in both our bacteriology and oncology segments, with sales in these areas reaching record levels. We have significantly increased our collaboration in automation and are on the verge of introducing several biomarkers onto automated platforms in China.
 
Several studies were completed throughout the year that helped improve our products market standing. We have optimized our organization, and with a rise in product demand, we are now closer to achieving positive cash flow. We are experiencing ongoing, consistent growth and a rising order intake that we are now able to manage effectively. I am eagerly anticipating further growth in 2024.
 
Nevertheless, the fourth quarter of 2023 could have been more successful. Some sales from the end of last year were delayed to 2024 due to issues with subcontractors and transportation. These delays caused a potential loss in turnover of 4 MSEK in 2023. However, of this, 2 MSEK has been recovered in January 2024.”
 
Anders Hultman, CEO
 
Reporting period October 1st – December 31st
· Net sales amounted to KSEK 9,511 (12,471).
· Profit after financial items amounted to KSEK -17,136 (-16,520)*.
· Cash flow from operating activities for the period amounted to KSEK -912 (-2,321).
· Earnings per share before and after dilution amounted to SEK -0.07 (-0.07).
· Cash and cash equivalents at the end of the period amounted to KSEK 50,723 (65,189).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
 
Reporting period January 1st – December 31st
· Net sales amounted to KSEK 43,039 (36,986).
· Profit after financial items amounted to KSEK -59,297 (-59,299)*.
· Cash flow from operating activities for the period amounted to KSEK -13,436 (-13,694).
· Earnings per share before and after dilution amounted to SEK -0.26 (-0.28).
· Cash and cash equivalents at the end of the period amounted to KSEK 50,723 (65,189).

* Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.
 
Events during the period October 1st – December 31st
· After the conclusion of the period, the warrant program has been implemented. The total number of warrants issued is 5,000,000, with a premium of 0.05 öre. The program has a duration of 3 years and is allocated among various groups, including the CEO, management team, other executives, and other employees. The strike price has been set at SEK 1, and the warrants are subscribed on market terms.

· AroCell presented information on the nomination committee’s proposal prior to the 2024 annual general meeting.
 
Events after the period
· A recent study has shown that serum thymidine kinase 1 (sTK1) levels can predict the survival of patients with metastatic prostate cancer. The results also suggest that sTK1 is useful in predicting which patients may benefit from chemotherapy with the drug docetaxel instead of a hormonal treatment. 

· Previously, AroCell announced a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sales of TUBEX® TF in Ethiopia. After navigating through the local regulatory process, AroCell has now obtained regulatory approval for TUBEX® TF in Ethiopia. 

· Ellen Dittberner, who serves as the CFO at AroCell, is currently on parental leave, and Lars Jakobsson has stepped in as the acting CFO.
 
Interim report January 1st – December 31st, 2023 (Link)